• IMMUNOTHERAPY:Immunotherapy, gene therapy combination shows promise against glioblastomaæææ In a new study, gene therapy deployed with immune checkpoint inhibitors demonstrates potential benefit for devastating brain cancer.**

immunsystem: En særlig slags immunceller reagerer forskelligt i mænd og kvinder æææThese immune cells differ in males and femalesæææA specific kind of immune cell behaves very differently in stressed males versus stressed females—resulting in women’s greater susceptibility to certain diseases. New research with mice may explain why. The study finds that females were more vulnerable to certain stress-related and allergic diseases than males because of distinct differences found in mast cells, a type of white blood cell that’sææææææ
#B cells:- Can tailored organoids reproduce immune-system events?æææ
immun-huskecellers mulige problem (TRM T-celler)æææ Possible Achilles' heel in key immune memory cellsæææ Genes involved in lipid metabolism are highly active in TRM cells, roughly 20- to 30-fold more active than in other types of T-cells.ææææææ
kræft: immunterapi – den fjerde søjle i kræftbehandlingen ud over kemoterapi, stråling og kirurgi.æææ Cancer immunotherapy comes of ageOncologists have long rested their treatment plans on three so-called "pillars"—chemotherapy, surgery, and radiation. But in recent years, scientists have been busily erecting a fourth pillar: immunotherapy. The idea of harnessing the immune system to fight cancer has already moved from the lab to the clinic, thanks to technologies such as checkpoint inhibitors and genetically engineered immune ceææææææ
CANCER: Using immune cells to deliver anti-cancer drugsæææ Biomedical engineers have created a smart, targeted drug delivery system using immune cells to attack cancers.ææææææ
Første biosimilære version af Mabthera tættere på europæisk lanceringTruxima har samme effekt, kvalitet og sikkerhed som Mabthera, mener EMA’s komité for humane lægemidler, CHMP.ææææææ
Første biosimilære version af Mabthera tættere på europæisk lanceringTruxima har samme effekt, kvalitet og sikkerhed som Mabthera, mener EMA’s komité for humane lægemidler, CHMP.ææææææ
kræft der ikke reagerer på immunterapi – pembrolizumab vil næppe virke mod kræftformer, der indeholder de genetiske mutationer JAK1 eller JAK2, som er kendt for at forhindre kræftsvulster i at genkende og modtage signaler fra T-celler for at stoppe deres vækst æææScientists discover why some cancers may not respond to immunotherapyæææScientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2, which are known to prevent tumors from recognizing or receiving signals from T cells to stop growing, will have little or no benefit from the immunotherapy drug pembrolizumab. This early-stage research has allowed them to determine for the first time why some people with advanced melanoma or advanced colææææææ
Nationalt Genom Center æææNyt center skal sætte skub i brug af personlig medicinæææEt nyt Nationalt Genom Center skal medvirke til, at patienter kan få mere effektiv behandling med færre bivirkninger.ææææææ
påvisning af hvilke T-killerceller der bedst kan angribe kræftcellerr æææNovel 'barcode' tracking of T cells in immunotherapy patients identifies likely cancer-killersæææA new discovery makes an important step in identifying which specific T cells within the diverse army of a person's immune system are best suited to fight cancer.ææææææ
Role for immune cells in cancer’s ability to evade immunotherapyOne of the main reasons cancer remains difficult to treat is that cancer cells have developed a multitude of mechanisms that allow them to evade destruction by the immune system. One of these escape mechanisms involves a type of immune cell called myeloid-derived suppressor cells (MDSCs). A recent study provides new insight into how MDSCs enable tumor cells to circumvent immune attack and offer thæææ
Shedding mutations may let cancer evade immunotherapyCancer cells may develop resistance to drugs known as checkpoint inhibitors by simply getting rid of mutations that would otherwise trigger the body’s disease-fighting immune system, research suggests. Researchers conducted the study, aimed at determining why so-called immunotherapy can become ineffective over time, on cells from five lung cancer and head and neck cancer patients. A summary appeaææææææ
Shedding mutations may let cancer evade immunotherapyCancer cells may develop resistance to drugs known as checkpoint inhibitors by simply getting rid of mutations that would otherwise trigger the body’s disease-fighting immune system, research suggests. Researchers conducted the study, aimed at determining why so-called immunotherapy can become ineffective over time, on cells from five lung cancer and head and neck cancer patients. A summary appeaææææææ

Tegn abonnement på

BioNyt Videnskabens Verden (www.bionyt.dk) er Danmarks ældste populærvidenskabelige tidsskrift for naturvidenskab. Det er det eneste blad af sin art i Danmark, som er helliget international forskning inden for livsvidenskaberne.

Bladet bringer aktuelle, spændende forskningsnyheder inden for biologi, medicin og andre naturvidenskabelige områder som f.eks. klimaændringer, nanoteknologi, partikelfysik, astronomi, seksualitet, biologiske våben, ecstasy, evolutionsbiologi, kloning, fedme, søvnforskning, muligheden for liv på mars, influenzaepidemier, livets opståen osv.

Artiklerne roses for at gøre vanskeligt stof forståeligt, uden at den videnskabelige holdbarhed tabes.